United States & Eisai
4 shared events · Importance 3 · Last updated Jun 26, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
International
United States: The United States' actions and statements regarding the conflict with Iran significantly impacted global crude oil prices and influenced market sentiment.
Eisai: Eisai's stock tumbled and declined, contributing to the negative performance of some pharmaceutical companies.
May 18, 2026 · 23 articles
Business
United States: The United States is the target market for Grey Matters Health Inc.'s expansion of neuroimaging clinics, addressing a growing demand for Alzheimer's detection and treatment within the country.
Eisai: Eisai, in collaboration with Biogen, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Tech
Eisai: Eisai co-produces lecanemab (Leqembi), an anti-amyloid drug whose effectiveness was disputed by the Cochrane review, potentially leading to financial repercussions.
Apr 16, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how United States and Eisai interact across events, view sentiment trends, and discover connected entities.
Open Dashboard